Wednesday, June 10, 2026
🇺🇸 FDA

Drug profile · INN

reboxetine

EDRONAX

reboxetine (EDRONAX) is a norepinephrine transporter inhibitor. Associated with Pfizer Australia Pty Ltd.

TGA: approved
Patents linked 9
Pipeline programs 3
News articles 0
Drug details — reboxetine
Class
—
Route
—
Patents
9
Programs
3
Data quality
0.81
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

reboxetine (EDRONAX) is a norepinephrine transporter inhibitor. Associated with Pfizer Australia Pty Ltd.

Key facts

INN reboxetine
Brand EDRONAX
Mechanism Norepinephrine transporter inhibitor
Target Sodium-dependent noradrenaline transporter
Originator Pfizer Australia Pty Ltd

Mechanism of action

Norepinephrine transporter inhibitor

Primary target: Sodium-dependent noradrenaline transporter

Approval history

Authority Status Date
TGA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. AXS-12 (Reboxetine) Phase 3 · Axsome Therapeutics · Narcolepsy
  2. AXS-14 (Esreboxetine) Phase 3 · Axsome Therapeutics · Fibromyalgia
  3. INTENSIFY MDD Phase 3 · Disc Medicine · Major depressive disorder

Related & competitor drugs

Browse all drugs
  1. amitriptyline hydrochloride Norepinephrine transporter inhibitor
  2. atomoxetine hydrochloride Norepinephrine transporter inhibitor
  3. desipramine hydrochloride Norepinephrine transporter inhibitor
  4. desvenlafaxine fumarate Norepinephrine transporter inhibitor
  5. doxepin hydrochloride Norepinephrine transporter inhibitor
  6. duloxetine hydrochloride Norepinephrine transporter inhibitor

Related patents

Browse patents Pfizer Australia Pty Ltd patent hub

  1. US 12246023

    Use of reboxetine to treat narcolepsy

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12115165

    Use of reboxetine to treat narcolepsy

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11957686

    Compositions for delivery of reboxetine

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11883408

    Reboxetine to treat narcolepsy

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11364245

    Use of reboxetine to treat narcolepsy

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11351175

    Use of reboxetine to treat narcolepsy

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11185547

    Use of reboxetine to treat narcolepsy

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11135226

    Use of reboxetine to treat narcolepsy

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11020402

    Use of reboxetine to treat narcolepsy

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is reboxetine?

reboxetine (EDRONAX) is a norepinephrine transporter inhibitor. Associated with Pfizer Australia Pty Ltd.

What is the brand name for reboxetine?

EDRONAX is a marketed brand name for reboxetine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.